Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

RGLS

Regulus Therapeutics (RGLS)

Regulus Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RGLS
DateTimeSourceHeadlineSymbolCompany
18/05/202406:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
18/05/202406:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
18/05/202406:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
16/05/202422:00PR Newswire (US)Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerNASDAQ:RGLSRegulus Therapeutics Inc
10/05/202406:54Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RGLSRegulus Therapeutics Inc
10/05/202406:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGLSRegulus Therapeutics Inc
10/05/202406:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
10/05/202406:05PR Newswire (US)Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
06/05/202422:00PR Newswire (US)Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
30/04/202422:00PR Newswire (US)Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast SeriesNASDAQ:RGLSRegulus Therapeutics Inc
22/03/202407:05PR Newswire (US)Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
12/03/202421:32PR Newswire (US)Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of EquityNASDAQ:RGLSRegulus Therapeutics Inc
12/03/202421:30PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
19/01/202412:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
19/01/202412:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
18/01/202409:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
18/01/202409:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
13/01/202408:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RGLSRegulus Therapeutics Inc
10/01/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RGLSRegulus Therapeutics Inc
03/01/202408:05PR Newswire (US)Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
28/12/202308:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RGLSRegulus Therapeutics Inc
23/11/202300:00PR Newswire (US)Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:RGLSRegulus Therapeutics Inc
10/11/202308:39Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGLSRegulus Therapeutics Inc
10/11/202308:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
10/11/202308:05PR Newswire (US)Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
02/11/202323:00PR Newswire (US)Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
19/10/202323:00PR Newswire (US)Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
20/09/202321:00PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
13/09/202322:00PR Newswire (US)Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
05/09/202322:00PR Newswire (US)Regulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesNASDAQ:RGLSRegulus Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RGLS